Table 1.
Patient characteristics for the PORT and PORT-C cohorts (108 matched patient pairs). Significant p-values are marked in bold.
| Characteristics | PORT Cohort (1999–2016) | PORT-C Cohort (2004–2011) | p-Value | ||
|---|---|---|---|---|---|
| Median (Range) | Median (Range) | ||||
| Age (years) | 57.3 (39.0–84.3) | 57 (24–74) | 0.26 | ||
| Dose (Gy) | 60.0 (60–66) | 64.0 (56–68.4) | <0.001 | ||
| Number of pts | % | Number of pts | % | ||
| Age 0(<57)/1(≥57 years) |
51/57 | 47.2/52.8 | 53/55 | 49.1/50.9 | 0.79 |
| Gender Male/female |
90/18 | 88.3/11.7 | 88/20 | 81.5/18.5 | 0.72 |
| Tumour localization Oral cavity/Oropharynx/Hypopharynx/Larynx |
31/55/6/16 | 28.7/50.9/5.5/14.9 | 31/59/18/0 | 28.7/54.6/16.7/0 | 1.00 |
| Grading 1,2/3 |
51/57 | 47.2/52.8 | 45/63 | 41.7/58.3 | 0.10 |
| R status 0/1/missing |
100/8 | 92.6/7.4 | 59/49 | 54.6/45.4 | <0.001 |
| ECE status 0/1/missing |
85/23 | 78.7/21.3 | 85/23 | 78.7/21.3 | 1.00 |
| p16 overexpression 0/1 |
71/37 | 65.7/34.3 | 67/41 | 62.0/38.0 | 0.57 |
| T stage 1,2/3,4 |
74/34 | 68.5/31.5 | 69/39 | 63.9/36.1 | 0.47 |
| N stage 0,1/2,3 |
68/40 | 63.0/37.0 | 37/71 | 38.0/62.0 | <0.001 |
| Locoregional control | 25 | 23.1 | 14 | 13.0 | 0.037 a |
| Distant metastases | 19 | 17.6 | 15 | 13.9 | 0.42 a |
| Overall survival | 46 | 42.6 | 31 | 28.7 | 0.12 a |
a Log-rank test.